Cited by 56Genetic Associations and EpidemiologyDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Imaging-wide association study: integrating imaging endophenotypes in GWAS

Open access
Xu, Zhiyuan, Wu, Chong, Pan, Wei·2017·NeuroImage

Abstract

A new and powerful approach, called imaging-wide association study (IWAS), is proposed to integrate imaging endophenotypes with GWAS to boost statistical power and enhance biological interpretation for GWAS discoveries. IWAS extends the promising transcriptome-wide association study (TWAS) from using gene expression endophenotypes to using imaging and other endophenotypes with a much wider range of possible applications. As illustration, we use gray-matter volumes of several brain regions of interest (ROIs) drawn from the ADNI-1 structural MRI data as imaging endophenotypes, which are then applied to the individual-level GWAS data of ADNI-GO/2 and a large meta-analyzed GWAS summary statistics dataset (based on about 74,000 individuals), uncovering some novel genes significantly associated with Alzheimer's disease (AD). We also compare the performance of IWAS with TWAS, showing much larger numbers of significant AD-associated genes discovered by IWAS, presumably due to the stronger link between brain atrophy and AD than that between gene expression of normal individuals and the risk for AD. The proposed IWAS is general and can be applied to other imaging endophenotypes, and GWAS individual-level or summary association data.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroimage.2017.07.036

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Integrating multiple imaging traits provides further improved diagnostic classification.

    “Groups are actively working to integrate multiple imaging traits together, providing an even further improved diagnostic classification [232, 233]”

    From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [232]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Xu, Z., Wu, C., & Pan, W.
Affiliations
University of Minnesota (US)
Corresponding author
Pan, Wei
Venue
NeuroImage
Publisher
Elsevier BV
Published
2017-10
Volume
159
Pages
159-169
ISSN
1053-8119 (ISSN-L)
OpenAlex
W2736837914
Cited by
56
References
55
Citations by year
2026: 4 · 2025: 3 · 2024: 1 · 2023: 13 · 2022: 6 · 2021: 13 · 2020: 8 · 2019: 6 · 2018: 1 · 2017: 1
FWCI
2.90
Type
journal article
Language
en
Open access
Locations
  • NeuroImage (acceptedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Biomedical Imaging and Bioengineering
  • Biogen Idec
  • BioClinica
  • Servier
  • Synarc
  • Genentech
  • Alzheimer's Disease Neuroimaging Initiative
  • University of Southern California
  • Merck
  • U.S. Department of Defense (W81XWH-12-2-0012)
  • Roche
  • GE Healthcare
  • University of California, San Diego
  • National Institute on Aging
  • Takeda Pharmaceuticals North America
  • Novartis Pharmaceuticals Corporation
  • Eisai
  • Foundation for the National Institutes of Health
  • Fujirebio US
  • National Institutes of Health (U01 AG024904)
  • Pfizer
  • Northern California Institute for Research and Education
  • Eli Lilly and Company
  • Alzheimer's Association
  • Bristol-Myers Squibb
  • Health Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
transcriptome-wide association study, gray matter volume, Alzheimer's disease, brain atrophy, risk genes, statistical power, ADNI
MeSH terms
Alzheimer Disease, Genotype, Humans, Genome-Wide Association Study, Endophenotypes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review